Better renal function preservation is associated with decreased cancer-specific death risk among patients who have an estimated glomerular filtration rate (eGFR) below 85 mL/min/1.73 m2 after surgery for organ-confined renal cell carcinoma, a study found.
For the study, researchers conducted a literature review and network meta-analysis of phase 2/3 randomized controlled trials of approved first-line TKI therapies for mRCC.
The investigators observed significantly higher postoperative CTC counts in the open radical nephrectomy group compared with the other 3 groups in the study.
The decision to adopt bevacizumab could be appraised by the prior level of uptake among their peers in their medical community.
A study of an Asian population failed to find a link between the virus and malignancies outside of the liver.
Axitinib plus pembrolizumab is recommended as first-line therapy for patients with favorable-risk clear cell advanced renal cell carcinoma, according to an updated position statement from the Society for Immunotherapy of Cancer.
Results from the phase 3 S-TRAC clinical trial suggested that for selected young and otherwise healthy patients, toxicities of sunitinib are manageable.
Proangiogenic or proimmunogenic genomic and transcriptomic signatures in the tumor microenvironment may have predictive value.
Findings underscore the limited generalizability of clinical trial results to patients in the real world.
Next-generation sequencing is being increasingly used to characterize the diversity of T-cell and B-cell receptors in individuals.
